Hospital Universitario Infanta Sofía

Running trials

• Recruiting

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  NCT07323316· Ad scientiam· Source

• Recruiting

  A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

  NCT07465757· Phase 2· Puma Biotechnology, Inc.· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  2025-523670-17-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  NCT07478991· Phase 3· PETHEMA Foundation· Source

• Recruiting

  Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)

  2025-521709-42-00· Phase 3· LETI Pharma S.L.U.· Source

• Recruiting

  A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

  2025-525127-27-00· Phase 1/2· Aurinia Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

  NCT07486934· Phase 3· Dyne Therapeutics· Source

• Recruiting

  A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy

  2025-522979-29-00· Phase 3· Fundacion PETHEMA· Source

• Recruiting

  AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07509307· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07481630· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Treatment for Ph-negative ALL for Adults up to 65 Years

  NCT07443592· PETHEMA Foundation· Source

• Recruiting

  Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients

  NCT07372170· Infanta Leonor University Hospital· Source

• Active, not recruiting

  Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

  NCT07160608· Phase 2· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial

  2024-512132-29-00· Phase 2· Swiss Group for Clinical Cancer Research· Source

• Recruiting

  A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

  NCT06976268· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Recruiting

  The role of intra-abdominal pressure and point of care ultrasound to guide decongestive therapy in Heart Failure (ABDOPOCUS-HF)

  2024-512901-22-00· Phase 3· Fundacion Instituto De Investigacion Sanitaria Aragon· Source

• Recruiting

  Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism

  2024-511959-18-01· Phase 3· Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal· Source

• Active, not recruiting

  Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-508235-31-00· Phase 3· Almirall S.A.· Source

• Recruiting

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Phase 3· Novartis Pharmaceuticals· Source

• Enrolling by invitation

  Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

  NCT06138743· Phase 1/2· Sarepta Therapeutics, Inc.· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

  NCT05558319· Phase 3· PETHEMA Foundation· Source

• Active, not recruiting

  Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT

  2024-517008-12-00· Phase 3· Fundacion PETHEMA· Source

• Recruiting

  Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

  NCT04989647· Phase 3· The Central and Eastern European Gynecologic Oncology Group· Source

• Active, not recruiting

  Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

  NCT04877691· Phase 3· AstraZeneca· Source

• Recruiting

  LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  NCT04752722· Phase 1/2· enGene, Inc.· Source

• Active, not recruiting

  Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

  NCT04090736· Phase 3· PETHEMA Foundation· Source

• Recruiting

  Thoracic Tumours Register

  NCT02941458· Spanish Lung Cancer Group· Source

• Recruiting

  Computerized Registry of Patients With Venous Thromboembolism (RIETE)

  NCT02832245· Manuel Monreal· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myasthenia gravis5 recruiting
• Acute myeloid leukaemia2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Lupus (SLE)2 recruiting
• Myotonic dystrophy2 recruiting
• Obesity2 recruiting
• Osteoarthritis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Antiphospholipid syndrome1 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)

  NCT06837090· Grupo Espanol de Tumores Neuroendocrinos· Source

• Completed

  A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

  NCT05931367· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

  NCT05898841· Phase 4· Fundacion SEIMC-GESIDA· Source

• Completed

  Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load

  2022-503110-23-00· Phase 4· Fundacion Seimc Gesida· Source

• Completed

  A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

  NCT05357989· Phase 3· Annovis Bio Inc.· Source

• Completed

  Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

  2024-511263-28-00· Phase 4· Novartis Pharma AG· Source

• Completed

  CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY.

  2024-513123-17-00· Phase 3· Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

• Completed

  Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  NCT03555422· Phase 3· Karyopharm Therapeutics Inc· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Eosinophilic oesophagitis4 works · 0 trials